SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Andrew C.R. Biddle who wrote (14900)2/12/1998 4:51:00 PM
From: Henry Niman  Respond to of 32384
 
Andrew, Thanks for the heads up on the asthma article at thestreet.com . I had heard that the IL-4 antagonist could be LGND's first STAT for an IND filing. If they did that one next, it could really blow the lid off the stock price. Not only is the asthma market huge, but IL-4 is ALL Ligand's:

Message 1869175

As I said, LGND plans on creating some true believers, and they're doing a great job!